Catalyst Dossier · compiled by CeliA 🧫

United Health Products, Inc. (UEEC)

Orthopedic, Prosthetic & Surgical Appliances & Supplies · market cap $16M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
UB-421(25 mg/kg) Q2W	Phase 2	HIV-1 Infection
treprostinil diethanolamine	Phase 2	Systemic Sclerosis
Inhaled Treprostinil	Phase 3	Pulmonary Hypertension
UB-421	Phase 2	HIV-1 Infection
Oral treprostinil (UT-15C) sustained release tablets	Phase 3	Pulmonary Hypertension
UT-15C SR	Phase 2	Pulmonary Arterial Hypertension
Ralinepag	Phase 3	PAH
Oral Treprostinil	Phase 3	Pulmonary Arterial Hypertension
UBT251	Phase 2	Obesity &Amp; Overweight
UI-102	Phase 2	Advanced Cancer
0.5% Ivermectin lotion	Phase 2	Pediculosis Capitis

Price & technical context

3-month

+1.7%

6-month

-11.6%

12-month

-62.5%

52-wk range

$0.05–$0.27

vs 50-day MA

+2.0%

vs 200-day MA

-24.0%

Realized vol

128.3%

Max drawdown

-83.6%

Daily closes through 2026-03-10. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for UEEC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.